IP Library Granted Patent US 9,394,524
Granted Patent B2
US 9,394,524 · App. 12/753,386 · Granted Jul 19, 2016

Chemical approaches for generation of induced pluripotent stem cells

Inventors: Tongxiang Lin (San Diego, CA); Wenlin Li (San Diego, CA); Sheng Ding (Pasadena, CA)
Assignee: The Scripps Research Institute
C12N5/0696C12N15/85C12N2500/14C12N2501/01C12N2501/065C12N2501/15C12N2501/602C12N2501/603C12N2501/605C12N2501/608C12N2501/727C12N2506/08C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,394,524
App. No.
12/753,386
Granted
Jul 19, 2016
Kind
B2
Abstract

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Claims (11)

1. A method of producing an induced pluripotent stem cell from a mammalian non-pluripotent cell, the method comprising

(a) introducing into the mammalian non-pluripotent cell, one or more expression cassettes comprising an Oct4 polynucleotide, a Sox2 polynucleotide, and a Klf4 polynucleotide, and

(b) contacting the cell of step (a) with a TGFβ receptor/ALK5 inhibitor and a GSK-3 inhibitor,

thereby producing an induced pluripotent stem cell from the mammalian non-pluripotent cell.

2. The method of claim 1 , further comprising contacting the cell with a second agent selected from the group consisting of a MEK inhibitor and an Erk inhibitor.

3. The method of claim 2 , wherein the second agent is a MEK inhibitor.

4. The method of claim 1 , further comprising contacting the mammalian non-pluripotent cell with a histone deacetylase (HDAC) inhibitor.

5. The method of claim 1 , wherein the TGFβ receptor/ALK5 inhibitor is selected from the group consisting of: A-83-01 and SB431542.

6. The method of claim 2 or claim 3 , wherein the MEK inhibitor is PD0325901.

7. The method of claim 1 , wherein the GSK-3 inhibitor is selected from the group consisting of: CHIR99021, CHIR98014, and 6-bromoindirubin-3′-oxime (BIO).

8. The method of claim 1 , wherein the one or more expression cassettes further comprises a c-Myc polynucleotide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2010
From: SHI, YAN; DESPONTS, CAROLINE; LIN, TONGXIANG; LI, WENLIN; DING, SHENG; ZHU, SAIYONG
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 024605/0300 →
Continuity (4)
Continuation In Part PCTUS2009037429 · Mar 17, 2009
Provisional Application 61069956 · Mar 17, 2008
Provisional Application 61197986 · Oct 31, 2008
Related Publication 20100267141A1 · Oct 21, 2010